The goal of this clinical trial is to learn if the DAPHNE chatbot can improve caregiver engagement, usability, and integration of social care support tools into clinical workflows in caregivers of pediatric patients receiving care at the Nationwide Children's Hospital Primary Care Center (NCH PCC). This is a pilot randomized clinical trial. The main questions it aims to answer are: * Is the DAPHNE chatbot usable, acceptable, and minimally burdensome for caregivers over a 6-month period? * Can the DAPHNE chatbot be effectively integrated into primary care provider workflows? Researchers will compare the DAPHNE chatbot intervention arm to the standard of care control arm to see if the intervention improves caregiver-reported outcomes and provider workflow integration. Participants that are patients will be randomly assigned to either the DAPHNE chatbot group or the standard of care group. Complete surveys assessing usability, acceptability, and burden and participate in brief qualitative interviews to share feedback on their experience. Participants that are Primary Care providers will discuss integration of DAPHNE into clinical workflows and complete workflow integration assessments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
System Usability Scale (SUS)
Timeframe: 1 month post-baseline and 3 months post-baseline for Caregivers. Providers will complete this at baseline only.
Web Evaluation Questionnaire (WEQ)
Timeframe: 1 month and 3 months post-baseline
Patient Comprehension Questionnaire (PCQ)
Timeframe: Baseline and 3 months post-baseline
Feasibility of Intervention Measure (FIM)
Timeframe: Caregivers will complete at 3 months and 6 months post-baseline. Providers will complete at baseline and 6 months post-baseline.
Retention Rate
Timeframe: 1 month, 3 months, and 6 months post-baseline
Social Determinants of Health
Timeframe: Caregivers will complete at baseline, 3 months post-baseline, and 6 months post-baseline.